1459 GMT - AstraZeneca's trial results for breast cancer pill Camizestrant are a material positive surprise and clear the first of its major late-stage catalysts for this year, Barclays analysts say in a note. The British pharma giant's results showed the drug candidate helped patients live for longer without their disease worsening. AstraZeneca guides for a more than $5 billion peak sales potential, whereas Barclays anticipates $3.6 billion. The company indicated it would release most key results in 2H, leading to the analysts expecting publication in the middle of the summer. Shares are up 0.1% at 119.46 pounds.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 26, 2025 09:59 ET (14:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。